Cargando…
Variations in MAP kinase gladiators and risk of differentiated thyroid carcinoma
Thyroid carcinoma (TC) accounts for ~2.1% of newly diagnosed cancer cases. Mutations in KRAS, HRAS, NRAS and BRAF are primary participants in the development and progression of various types of malignancy, including differentiated TC (DTC). Therefore, the present prospective cohort study aimed to sc...
Autores principales: | Rashid, Faiza A., Bhat, Ghulam Hassan, Khan, Mosin S., Tabassum, Sobia, Bhat, Mohammad Hayat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739702/ https://www.ncbi.nlm.nih.gov/pubmed/35003743 http://dx.doi.org/10.3892/mco.2021.2478 |
Ejemplares similares
-
The gladiators
por: Koestler, Arthur
Publicado: (1967) -
VE1 immunohistochemistry is an adjunct tool for detection of BRAF
(V600E) mutation: Validation in thyroid cancer patients
por: Rashid, Faiza A., et al.
Publicado: (2020) -
About gladiators and a sacred disease
por: Kattner, Aila Akosua
Publicado: (2022) -
GLADIATOR: a global approach for elucidating disease modules
por: Silberberg, Yael, et al.
Publicado: (2017) -
Vitamin D status in Psoriasis: impact and clinical correlations
por: Bhat, Ghulam Hassan, et al.
Publicado: (2022)